<DOC>
	<DOC>NCT02805166</DOC>
	<brief_summary>The purpose of this study is to estimate the safety and efficacy of PEG-rhG-CSF in patients with lung cancer,head and neck cancer,colorectal cancer,and ovarian cancer receiving multi-cycle chemotherapy.</brief_summary>
	<brief_title>PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Patients with age ≥ 18 years diagnosis of lung cancer,head and neck cancer,colorectal cancer,ovarian cancer Karnofsky Performance Status ≥ 70 life expectancy of at least 3 months Written informed consent are acquired uncontrolled infection,Temperature is 38.0 ℃ or higher pregnancy Other situations that investigators consider as contraindication for this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>PEG-rhG-CSF</keyword>
</DOC>